BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL).
In initial preclinical studies, BTM-3566 has shown exceptional in-vitro and in vivo activity against DLBCL, inducing rapid, durable, and complete remission in multiple tumor models.
An IND application for BTM-3566 in B-cell malignancies has been submitted and the phase 1 study allowed to proceed by FDA. Bantam is currently seeking its next round of investment to initiate this first-in-humans clinical trial.
